AM

Alexander Mayweg

Managing Director at Versant Ventures

Basel, Basel

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Drug Discovery
Medicinal Chemistry
Organic Synthesis
Pharmaceutical Industry
Drug Development
Infectious Diseases
Lead Change
Leadership
Life Sciences
Drug Design
R&D
Organic Chemistry
High Throughput Screening
Oncology
Virology
Chemistry
Cheminformatics
Biotechnology
Lifesciences
Biochemistry

Education

Lists including Alexander

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Investments

Bright Peak Therapeutics

Series A

Total Funding: $230M

SixPeaks Bio

Series A

Total Funding: $30M

Launchpad Therapeutics

Series A

Total Funding: $30M

Vector BioPharma

Series A

Total Funding: $30M

Cimeio Therapeutics

Series A

Total Funding: $50M

T-knife

Series A

Total Funding: $200M

Monte Rosa Therapeutics

Series A

Total Funding: $220M

Matterhorn Biosciences

Series Unknown

Total Funding: $30M

Black Diamond Therapeutics

Series A

Total Funding: $190M

Work Experience

VV
Versant Ventures

2016

  • Managing Director

    2020

  • Partner

    2018 - 2020

  • Venture Partner

    2017 - 2017

  • Entrepreneur in Residence

    2016 - 2016

SB
SixPeaks Bio

2022

  • President of the Board of Directors

    2022

GB
Granite Bio

2021

  • President of the Board of Directors

    2021

RR
Red Ridge Bio

2022

  • President of the Board of Directors

    2022

Serac Therapeutics

2022

  • President of the Board of Directors

    2022

Revelio Therapeutics

2022

  • Chairman of the Board

    2022

BP
Bright Peak Therapeutics

2017

  • Board Member

    2017

RT
Ridgeline Therapeutics

2017

  • President and CSO

    2017

ET
Enterprise Therapeutics

2018

  • Board Director

    2018

MR
Monte Rosa Therapeutics

2018 - 2024

  • Board Director

    2018 - 2024